HACKENSACK, N.J., Jan. 21, 2016 /PRNewswire/ -- Champions Oncology
(NASDAQ:CSBR) today announced that it has initiated a sponsored
prospective correlative trial of patient derived xenograft modeling
(PDX or Champions TumorGraft® PDX models)
in patients with metastatic or recurrent sarcoma. Mount Sinai
Hospital in Toronto, Canada is the
first clinical site to enroll patients in the newly-opened
study.
Albiruni Abdul Razak, MD, Medical Oncologist at the Sarcoma
Cancer Program at Mount Sinai Hospital stated, "We are very pleased
to be among the clinical sites participating in this trial.
Sarcomas are highly complex and rare cancers, and our entire team
is dedicated to improving outcomes in patients affected by all
forms of sarcoma."
"This trial is based on the growing dataset supporting the
clinical predictive value of Champions TumorGraft PDX models, and
represents the first company-sponsored trial to prospectively
evaluate PDX accuracy and clinical utility in predicting patient
response to drug therapy," said Angela
Davies, MD, Chief Medical Officer at Champions
Oncology. She continued, "We will leverage the same clinical
operations capabilities that we utilize for our ongoing and future
co-clinical PDX trials conducted in partnership with biopharma for
this initiative. Overall, this trial aligns with our strategy
to establish the clinical utility of Champions TumorGraft models
not only for individual patients but also for oncology drug
development."
The trial will enroll patients with metastatic sarcoma who have
had no more than one prior systemic treatment for metastatic
disease, and patients with recurrent sarcoma at relapse. In the
study, Champions TumorGraft PDX models will be developed from each
patient's fresh tumor tissue, available through biopsy or a
surgical procedure. Treating physicians will then select
drugs to be tested in the patient's personalized PDX models to
evaluate drug sensitivity. The study will assess the degree
of correlation between the patient's tumor response and the tumor
response in the patient's corresponding PDX model as well as
clinical utility.
Dr. Davies concluded, "Identifying and developing the best drug
or drug combination for patients and optimizing oncology treatment
selection in the clinic is always the ultimate goal. We plan to
execute a broad program that supports the use of Champions
TumorGraft models as a valuable translational and clinical tool.
"
Additional information on the study can be found at
https://www.clinicaltrials.gov.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Champions
TumorGraft® technology platform is a novel
approach to personalizing cancer care based upon the implantation
of primary human tumors in immune deficient mice followed by
propagation of the resulting engraftments, or Champions TumorGraft
PDX models, in a manner that preserves the biological
characteristics of the original human tumor in order to determine
the efficacy of a treatment regimen. The Company uses this
technology in conjunction with related services to offer solutions
for two customer groups: Personalized Oncology Solutions, in
which results help guide the development of personalized treatment
plans, and Translational Oncology Solutions, in which
pharmaceutical and biotechnology companies seeking personalized
approaches to drug development can lower the cost and increase the
speed of developing new drugs. PDX tumor models in the
Champions TumorGraft platform are procured through agreements with
a number of institutions in the U.S. and overseas as well as
through Champions' Personalized Oncology Solutions business. For
more information, please visit www.championsoncology.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-announces-initiation-of-prospective-correlative-trial-in-sarcoma-300207819.html
SOURCE Champions Oncology, Inc.